Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Vyndaqel Success Interfering With Alnylam's Plans

Blockbuster Status In Sight For Pfizer Drug

Executive Summary

Alnylam wants to emulate success of Eylea and Revlimid in amyloidosis– but Pfizer could spoil the plan.

You may also be interested in...



Intellia Achieves Gene-Editing Breakthrough With First In Vivo CRISPR Therapy

The first use of CRISPR/Cas9 in humans shows promising safety and efficacy against rare disease ATTR, and opens up the possibility of treating many genetic diseases.

Alnylam's Phase III Results For Vutrisiran Are 'Foundation' For Amyloidosis Expansion

The results are in for hATTR amyloidosis with polyneuropathy, while results for hereditary and wild-type ATTR with cardiomyopathy are expected later this year.

Alnylam Wins FDA Approval For Givlaari, Its Second RNAi Drug

Givosiran was approved by the US FDA for the treatment of acute hepatic porphyria, a rare generic blood disorder, nearly three months ahead of the action date.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel